Seung Min Jung

Dr. Seung Min Jung

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Immune Network
Verified
Journal Article
Open access
PDF file
SJSeung Min Jung
Seung Min Jung
WKWan-Uk Kim
Wan-Uk Kim
Jung SM, et al. Immune Netw. 2022 Feb;22(1):e9. https://doi.org/10.4110/in.2022.22.e9

1 January 2014 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
SJSeung Min Jung
Seung Min Jung
KKKyoung Woon Kim
Kyoung Woon Kim
CYChul-Woo Yang
Chul-Woo Yang
SPSung-Hwan Park
Sung-Hwan Park
JJJi Hyeon Ju
Ji Hyeon Ju
Bone homeostasis, which involves formation and resorption, is an important process for maintaining adequate bone mass in humans. Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation and bone loss, leading to joint destruction and deformity, and is a representative disease of disrupted bone homeostasis. The bone loss and joint destruction are mediated by immunological insults by proinflammatory cytokines and various immune cells. The connection between bone and immunity has been intensely studied and comprises the emerging field of osteoimmunology. Osteoimmunology is an interdisciplinary science investigating the interplay between the skeletal and the immune systems. The main contributors in osteoimmunology are the bone effector cells, such as osteoclasts or osteoblasts, and the immune cells, particularly lymphocytes and monocytes. Physiologically, osteoclasts originate from immune cells, and immune cells regulate osteoblasts and vice versa. Pathological conditions such as RA might affect these interactions, thereby altering bone homeostasis, resulting in the unfavorable outcome of bone destruction. In this review, we describe the osteoclastogenic roles of the proinflammatory cytokines and immune cells that are important in the pathophysiology of RA.

27 February 2019 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
Wallace Chak Sing LauWallace Chak Sing Lau
Wallace Chak Sing Lau
FCFaith Chia
Faith Chia
LDLeonila Dans
Leonila Dans
AHAndrew Harrison
Andrew Harrison
THTsu Yi Hsieh
Tsu Yi Hsieh
SYSwan Sim Yeap
Swan Sim Yeap

28 January 2017 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
YNYoojun Nam
Yoojun Nam
YRYeri Rim
Yeri Rim
SJSeung Min Jung
Seung Min Jung
JJJi Hyeon Ju
Ji Hyeon Ju
The native articular cartilage lacks the ability to heal. Currently, ex vivo expanded chondrocytes or bone marrow-derived mesenchymal stem cells are used to regenerate the damaged cartilage. With unlimited self-renewal ability and multipotency, human induced pluripotent stem cells (hiPSCs) have been highlighted as a new replacement cell source for cartilage repair. Still, further research is needed on cartilage regeneration using cord blood mononuclear cell-derived hiPSCs (CBMC-hiPSCs). Human iPSCs were generated from CBMCs using the Sendai virus. The characterization of CBMC-hiPSCs was performed by various assays. Embryonic bodies (EBs) were obtained using CBMC-hiPSCs, and outgrowth cells were induced by plating the EBs onto a gelatin-coated plate. Expanded outgrowth cells were detached and dissociated for chondrogenic differentiation. Outgrowth cells were differentiated into chondrogenic lineage with pellet culture. Chondrogenic pellets were maintained for 30 days. The quality of chondrogenic pellets was evaluated using various staining and genetic analysis of cartilage-specific markers. Reprogramming was successfully done using CBMCs. CBMC-hiPSCs (n = 3) showed high pluripotency and normal karyotype. Chondrogenic pellets were generated from the outgrowth cells derived from CBMC-hiPSC EBs. The generated chondrogenic pellets showed high expression of chondrogenic genetic markers such as ACAN, COMP, COL2A1, and SOX9. The production of extracellular matrix (ECM) proteins was confirmed by safranin O, alcian blue and toluidine blue staining. Expression of collagen type II and aggrecan was detected in the accumulated ECM by immunohistological staining. Chondrogenic pellets showed low expression of fibrotic and hypertrophic cartilage marker, collagen type I and X. This study reveals the potential of CBMC-hiPSCs as a promising candidate for cartilage regeneration.


15 April 2017 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
SASung Soo Ahn
Sung Soo Ahn
BYByung-Woo Yoo
Byung-Woo Yoo
SJSeung Min Jung
Seung Min Jung
SLSang-Won Lee
Sang-Won Lee
YPYong-Beom Park
Yong-Beom Park
JSJason Jungsik Song
Jason Jungsik Song
Objective.: To evaluate the clinical significance of the 2016 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR)/Pediatric Rheumatology International Trials Organization (PRINTO) classification criteria for macrophage activation syndrome (MAS) in patients with adult-onset Still disease (AOSD).Methods.: We performed a retrospective analysis of patients with AOSD with fever who were admitted to Severance Hospital between 2005 and 2016. The patients with AOSD were evaluated for MAS using the 2016 classification criteria for MAS. Clinical features, laboratory findings, and overall survival were analyzed. Logistic regression analysis was used to evaluate the factors associated with in-hospital mortality.Results.: Among 64 patients with AOSD, 36 (56.3%) were classified as having MAS. The overall survival rate was significantly lower in patients with MAS than in those without (67% vs 100%, p < 0.001). Multivariate analysis showed that a low erythrocyte sedimentation rate, a low albumin level, an increase in ferritin of over 2 folds, and the development of MAS on admission were significantly associated with mortality in patients with AOSD.Conclusion.: The 2016 EULAR/ACR/PRINTO classification criteria for MAS are potentially useful for the identification of patients with AOSD at high risk for a poor outcome. Febrile patients with AOSD should be monitored with the 2016 classification criteria for MAS in the early diagnosis and proper treatment of MAS.